Zofenopril and ramipril and acetylsalicylic acid in postmyocardial infarction patients with left ventricular systolic dysfunction

Borghi, Claudio; Ambrosioni, Ettore; Omboni, Stefano; Cicero, Arrigo F G; Bacchelli, Stefano; Esposti, Daniela Degli; Vinereanu, Dragoş; Ambrosio, Giuseppe; Zava, Dario

doi:10.1097/hjh.0b013e3283605cd8

Cited by 11 publications

(10 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…7,8 Thus, the knowledge of the clinical profiles of ACE inhibitors in these settings is essential. For example, congestive heart failure is frequently evident in post-AMI patients and significantly contributes to a high mortality and morbidity risk; the presence of renal dysfunction is a further negative complication increasing the 1-month and 1-year mortality and adverse cardiac events.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy of Zofenopril Compared With Placebo and Other Angiotensin-converting Enzyme Inhibitors in Patients With Acute Myocardial Infarction and Previous Cardiovascular Risk Factors: A Pooled Individual Data Analysis of 4 Randomized, Double-blind, Controlled, Prospective Studies

Borghi

Omboni

Reggiardo

et al. 2017

Journal of Cardiovascular Pharmacology

Self Cite

View full text Add to dashboard Cite

Abstract:In the Survival of Myocardial Infarction Long-term Evaluation (SMILE) 1, 3, and 4 studies, early administration of zofenopril in acute myocardial infarction showed to be prognostically beneficial versus placebo or ramipril. The SMILE-2 showed that both zofenopril and lisinopril are safe and showed no significant differences in the incidence of major cardiovascular (CV) complications. In this pooled analysis of individual data of the SMILE studies, we evaluated whether the superior efficacy of zofenopril is maintained also in patients with ≥1 CV risk factor (CV+, n = 2962) as compared to CV− (n = 668). The primary study end point was set to 1-year combined occurrence of death or hospitalization for CV causes. The risk of CV events was significantly reduced with zofenopril versus placebo either in the CV+ (−37%; hazard ratio: 0.63; 95% confidence interval: 0.51–0.78; P = 0.0001) or in the CV− group (−55%; hazard ratio: 0.45; 0.26–0.78; P = 0.004). Also, the other angiotensin-converting enzyme inhibitors reduced the risk of major CV outcomes, though the reduction was not statistically significant versus placebo (CV+: 0.78; 0.58–1.05; P = 0.107; CV−: 0.71; 0.36–1.41; P = 0.334). The benefit was larger in patients treated with zofenopril than other angiotensin-converting enzyme inhibitors, with a statistically significant difference for CV+ (0.79; 0.63–0.99; P = 0.039) versus CV− (0.62; 0.37–1.06; P = 0.081). In conclusion, zofenopril administered to patients after acute myocardial infarction has a positive impact on prognosis, regardless of the patient's CV risk profile.

show abstract

Section: Discussionmentioning

confidence: 99%

“…The SMILE project further encompassed in-depth analyses of patient subgroups such as patients with diabetes 6,7 or hypertension. 8,9 …”

Section: Introductionmentioning

confidence: 99%

Efficacy of Zofenopril Compared With Placebo and Other Angiotensin-converting Enzyme Inhibitors in Patients With Acute Myocardial Infarction and Previous Cardiovascular Risk Factors: A Pooled Individual Data Analysis of 4 Randomized, Double-blind, Controlled, Prospective Studies

Borghi

Omboni

Reggiardo

et al. 2017

Journal of Cardiovascular Pharmacology

Self Cite

View full text Add to dashboard Cite

show abstract

“…This retrospective analysis of the SMILE-4 study confirmed the good efficacy of Zofenopril and ASA in the prevention of long-term cardiovascular outcomes. The superiority of Zofenopril versus Ramipril was particularly evident in patients with isolated systolic hypertension (n=131, 0.48 (0.23-0.99), P = 0.045) [11].…”

Section: Discussionmentioning

confidence: 99%

Antiremodelling Efficacy and Clinical Safety of Zofenopril in Patients with Grade 1and 2 Hypertension

Khamidullaeva¹,

Abdullaeva²,

Хафизова³

et al. 2015

Int J Biomed

View full text Add to dashboard Cite

Objective: to estimate the antihypertensive, antiremodelling efficacy and clinical tolerability of the monotherapy with Zofenopril in patients with Grade 1 and 2 hypertension (HT 1 and 2) Materials and Methods: The study included 30 patients aged from 30 to 60 years with HT 1 and 2 (ESH/ESC, 2013) without severe comorbidities and cardiovascular complications. Zofenopril was prescribed as monotherapy to HT patients who had never been treated before or patients after one week of lavage from previous antihypertensive therapy, who did not reach target levels of blood pressure (BP). Before and during treatment all patients were checked on office BP using Korotkov's method and ambulatory blood pressure monitoring (ABPM). Echocardiography and Doppler sonography were carried out by standard methods using the recommendations of the American Society of Echocardiography. Intima-media thickness (IMT) of the carotid artery and brachial artery was measured by a 7.5 MHz high-resolution ultrasound. Assessment of flow-mediated dilation (FMD) of the brachial artery was used as a method of determining endothelial function.Results: A 12-week monotherapy with Zofenopril in average daily dose of 36.0±9.54 mg showed a high antihypertensive efficacy and a good safety profile without side effects. We noted a reliable decrease in systolic BP (SBP), diastolic BP (DBP), mean BP, and pulse pressure by -19.53±5.93%, -18.64±7.18%, -19.05±6.14%, and -20.65±12.07%, respectively. Target SBP, DBP, and SBP+DBP were reached in 90%, 86.6%, and 83.3% of patients, respectively. We found a significant regression of LVH, significant improvement in volume indicators of LV echogeometry and parameters of FMD of the brachial artery, as well as a decrease in IMT of carotid and brachial arteries. Monotherapy with Zofenopril showed metabolic neutrality regarding the lipid and carbohydrate metabolism, a good safety profile without the side effects and undesired events.

show abstract

“…Zofenopril calcium, a prodrug of the active compound zofenoprilat, is an ACE-inhibitor which has been successfully and safely employed in the treatment of essential hypertension [ 11 ] and acute myocardial infarction or heart failure [ 12 ], also in subgroups of patients with high BP [ 13 , 14 ]. In subjects with essential hypertension zofenopril has been shown to be as effective as beta-blockers [ 15 ], diuretics [ 16 ], calcium channel blockers [ 17 ], other ACE-inhibitors [ 18 , 19 ], and Angiotensin Receptor Blockers (ARBs) [ 20 , 21 ].…”

Section: Introductionmentioning

confidence: 99%

Blood Pressure Response to Zofenopril or Irbesartan Each Combined with Hydrochlorothiazide in High-Risk Hypertensives Uncontrolled by Monotherapy: A Randomized, Double-Blind, Controlled, Parallel Group, Noninferiority Trial

Malacco

Omboni

Parati

2015

International Journal of Hypertension

Self Cite

View full text Add to dashboard Cite

In this randomized, double-blind, controlled, parallel group study (ZENITH), 434 essential hypertensives with additional cardiovascular risk factors, uncontrolled by a previous monotherapy, were treated for 18 weeks with zofenopril 30 or 60 mg plus hydrochlorothiazide (HCTZ) 12.5 mg or irbesartan 150 or 300 mg plus HCTZ. Rate of office blood pressure (BP) response (zofenopril: 68% versus irbesartan: 70%; p = 0.778) and 24-hour BP response (zofenopril: 85% versus irbesartan: 84%; p = 0.781) was similar between the two treatment groups. Cardiac and renal damage was equally reduced by both treatments, whereas the rate of carotid plaque regression was significantly larger with zofenopril. In conclusion, uncontrolled monotherapy treated hypertensives effectively respond to a combination of zofenopril or irbesartan plus a thiazide diuretic, in terms of either BP response or target organ damage progression.

show abstract

Zofenopril and ramipril and acetylsalicylic acid in postmyocardial infarction patients with left ventricular systolic dysfunction

Abstract: This retrospective analysis of the SMILE-4 study confirmed the good efficacy of zofenopril and ASA in the prevention of long-term cardiovascular outcomes also in the subgroup of patients with hypertension.

Cited by 11 publications

References 45 publications

Efficacy of Zofenopril Compared With Placebo and Other Angiotensin-converting Enzyme Inhibitors in Patients With Acute Myocardial Infarction and Previous Cardiovascular Risk Factors: A Pooled Individual Data Analysis of 4 Randomized, Double-blind, Controlled, Prospective Studies

Efficacy of Zofenopril Compared With Placebo and Other Angiotensin-converting Enzyme Inhibitors in Patients With Acute Myocardial Infarction and Previous Cardiovascular Risk Factors: A Pooled Individual Data Analysis of 4 Randomized, Double-blind, Controlled, Prospective Studies

Antiremodelling Efficacy and Clinical Safety of Zofenopril in Patients with Grade 1and 2 Hypertension

Blood Pressure Response to Zofenopril or Irbesartan Each Combined with Hydrochlorothiazide in High-Risk Hypertensives Uncontrolled by Monotherapy: A Randomized, Double-Blind, Controlled, Parallel Group, Noninferiority Trial

Contact Info

Product

Resources

About